---
content_type: page
title: Calendar
uid: 6eda4710-3eb5-1b0c-1b02-ce3c36372ba4
---

Session Key
-----------

L = Lecture

R = Recitation

E = Exam

Lecturer Key
------------

|  {{< br >}}{{< br >}} PD = Prof. Peter Dedon {{< br >}}{{< br >}} MM = Dr. Mark Murcko {{< br >}}{{< br >}} ST = Prof. Steven Tannenbaum {{< br >}}{{< br >}}  |  {{< br >}}{{< br >}}   CK = Dr. Charles Knutson {{< br >}}{{< br >}}   GL = Guest lecturer {{< br >}}{{< br >}}   TA = Teaching assistants {{< br >}}{{< br >}}  

| SES # | TOPICS | LECTURERS | KEY DATES |
| --- | --- | --- | --- |
| {{< td-colspan 4 >}}**Overview of the Drug Discovery Process; Fundamental Principles**{{< /td-colspan >}} ||||
| L1 | Introduction and Fundamentals | PD, MM, ST | &nbsp; |
| L2 | Overview of Drug Development 1 | MM | &nbsp; |
| L3 | Overview of Drug Development 2 | MM | &nbsp; |
| R1 | Fundamentals | PD | &nbsp; |
| L4 | Biochemistry Review Exercise | CK | &nbsp; |
| L5 | Uptake and Distribution | PD | &nbsp; |
| L6 | Dr. Keith Hoffmaster, Novartis: Drug Transporters 1 | GL | &nbsp; |
| L7 | Dr. Keith Hoffmaster, Novartis: Drug Transporters 2 | GL | Drug Metabolism Problem Sets Due |
| R2 | Drug Metabolism 1 | ST | &nbsp; |
| L8 | Drug Metabolism 2 | ST | &nbsp; |
| L9 | Drug Toxicity 1 | ST | &nbsp; |
| R3 | Lecture Review Session | TA | &nbsp; |
| L10 | Drug Toxicity 2 | ST | &nbsp; |
| L11 | Pharmacokinetics | PD | &nbsp; |
| R4 | Quiz Review | PD, TA |  {{< br >}}{{< br >}} Fundamentals Problem Set Due {{< br >}}{{< br >}} Pharmacokinetics Problem Set Due {{< br >}}{{< br >}}  |
| E || {{< td-colspan 3 >}}Exam{{< /td-colspan >}} |||
| {{< td-colspan 4 >}}**Case Studies and Literature Discussions; Case Study Project**{{< /td-colspan >}} ||||
| L12 | Case Study: Omeprazole Pharmacogenetics | PD | &nbsp; |
| R5 | Overview of Drug Development 3 | MM | Case Study Project Topic Due |
| L13 | Case Study | MM | &nbsp; |
| L14 | Case Study: Antibiotics | CK | &nbsp; |
| R6 | Project Help Session | TA | &nbsp; |
| L15 | Case Study | ST | &nbsp; |
| L16 | Dr. Alex Wood, MIT Senior Lecturer / Novartis: Case Study: Oncology Drugs | GL | &nbsp; |
| R7 | Project Help Session | TA | &nbsp; |
| L17 | Case Study: Statins | PD | &nbsp; |
| R8 | Project Help Session | TA | &nbsp; |
| L18 | Case Study: GWAS and Statin Toxicity | PD | &nbsp; |
| L19 | Dr. Bernard Fermini, Pfizer: Case Study: Cardiotoxicity | GL | &nbsp; |
| R9 | Project Help Session | TA | &nbsp; |
| L20 | Dr. Teresa Wright, Shire Pharmaceuticals: Preclinical Drug Development | GL | &nbsp; |
| R10 | Project Help Session | TA | &nbsp; |
| L21 | Dr. Keith Hoffmaster: Case Study: PK / PD | GL | &nbsp; |
| L22 | Case Study: Sarilumab Phase III Clinical Result | MM | &nbsp; |
| R11 | Prof. Doug Lauffenburger: Systems Pharmacology | GL | &nbsp; |
| L23 | Dr. Tess Schmalbach, Schmalbach LLC: The Clinical Size of Drug Development | GL | Case Study Project Paper Due